Expanding Medicare coverage to include anti-obesity medications would give tens of thousands of Mainers access to effective treatment, allowing more people to reclaim their health and re-engage ...

Medicare coverage would reduce out-of-pocket ... the pharma industry – and noted that "international prices for anti-obesity medications are much lower than US list prices and generally lower ...

Medicaid plans often put up barriers around newer classes of diabetes medications that offer cardioprotection, according to a ...

The Centres for Medicare and Medicaid Services (CMS) said late on Friday that it would not cover anti-obesity medicines ... prohibited coverage of these drugs under Medicare Part D, a relic ...

Health and Human Services Secretary Robert F. Kennedy Jr. attends a swearing in ceremony for Dr. Mehmet Oz to be ...

A daily pill from drugmaker Eli Lilly has shown similar effectiveness at helping people reduce blood sugar levels and lose weight compared to leading injectable GLP-1 drugs Mounjaro and Ozempic ...

shows that women are much more aware of and knowledgeable about the obesity drugs GLP-1/GIP receptor agonists (that include semaglutide and tirzepatide). The study is by Nadja Auerbach ...

According to KFF’s research, the new Trump executive order on small molecule drugs could lead to higher Medicare prescription drug prices and potentially higher Medicare Part D premiums.

Most of the weight lost by adults using an obesity medication came from fat mass. Researchers said careful monitoring of body composition is needed to protect muscle mass with obesity pharmacotherapy.

A new generation of obesity drugs is transforming patients’ lives, dividing medical experts, and spurring the biggest business battle in years. Known as GLP-1-based drugs, this medication class ...